Turn Therapeutics Business Summary

Turn Therapeutics Inc. (NASDAQ: TTRX) is a clinical-stage biotechnology firm that generates revenue through a hybrid model of strategic licensing, global supply agreements, and direct product commercialization. The company operates across three primary business segments: dermatology, advanced wound care, and infectious diseases, all underpinned by its proprietary PermaFusion® delivery technology. Its financial trajectory is currently driven by a major global supply and license agreement with Medline, which is expected to catalyze revenue generation in the wound care market throughout 2026, alongside milestones from its lead clinical asset, GX-03, a first-in-class IL-36/IL-31 inhibitor for atopic dermatitis. Within the pharmaceutical landscape, Turn Therapeutics competes with small-cap peers such as Anavex Life Sciences (AVXL), Bicycle Therapeutics (BCYC), and Invivyd (IVVD). Turn distinguishes itself by focusing on "non-systemic" medicine, providing localized, high-efficacy treatments that minimize systemic toxicity, positioning the company as a specialized player in the targeted immunology space. The company was founded by CEO Bradley Burnam, a regulatory expert with over 15 patents whose experience in navigating FDA pathways led the company’s successful transition to the NASDAQ in late 2025. The executive leadership includes Chief Medical Officer Dr. Neilesh Ghodadra, a renowned orthopedic surgeon, and Chief Accounting Officer Zuraiz Chaudhary, CPA, who manages the firm’s capital strategy. In February 2026, the team was significantly bolstered by the appointment of Dr. Robert Redfield, the 18th Director of the CDC, as Senior Advisor of Health Policy and Regulatory Affairs to oversee the clinical advancement of the company’s vaccine and inflammatory pipelines. The Board of Directors features high-pedigree members including Martin Dewhurst, a 30-year McKinsey M&A veteran, and Dr. Kent Kester, a global leader in infectious disease research. This leadership is supported by strategic backing from institutional investors and a commercial partnership with Medline, which provides the global infrastructure necessary for scaling Turn’s proprietary technology platforms.